PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia - Thermo Fisher Scientific has launched a webinar to prepare ICP users for the new United States Pharmacopeia chapters proposal (NYSE: TMO)
Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia

 

NewswireToday - /newswire/ - Cambridge, United Kingdom, 2010/07/15 - Thermo Fisher Scientific has launched a webinar to prepare ICP users for the new United States Pharmacopeia chapters proposal (NYSE: TMO).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific, Inc., the world leader in serving science, today announced an informative webinar to help users of inductively coupled plasma (ICP) technologies prepare for the introduction of the proposed United States Pharmacopeia (USP) chapters 232 and 233 on trace elemental impurities in pharmaceutical products. The educational presentation provides the pharmaceutical industry with valuable information about how ICP techniques can facilitate compliance with these emerging legislative requirements. The webinar, entitled “Preparing for the Proposed United States Pharmacopeia Chapters on Trace Elemental Impurities in Pharmaceuticals with ICP Techniques,” is now available to view on-demand.

Presented by Matthew Cassap, senior ICP applications specialist for Thermo Fisher Scientific, the comprehensive webinar discusses the limitations of the current USP method governing the analysis of heavy metals in pharmaceutical products. In addition, the webinar provides a historical background and detailed overview of the proposed new chapters.

The presentation features the Thermo Scientific iCAP 6000 Series ICP spectrometer, demonstrating the efficiency of ICP techniques for the reproducible analysis of trace elemental impurities in pharmaceuticals in compliance with the upcoming regulatory requirements. In addition, Thermo Scientific iTEVA Security Software plays a crucial role in legislative compliance efforts as it allows for optimization of instrument parameters and elimination of interferences, delivering maximum accuracy and reliability of results. The webinar will also discuss other elemental analysis techniques and how these can be utilized for the analysis of trace elemental impurities in pharmaceuticals.

Matthew Cassap comments: “The latest Thermo Scientific webinar is essential for pharmaceutical scientists who need to stay up-to-date with elemental analysis techniques and, in particular, ICP-OES and ICP-MS methodologies in order to meet future legislative requirements in pharmaceutical analysis. The proposed USP chapters mark a new era for the analysis of trace elemental impurities in pharmaceutical products and the industry must get ready for the change. The Thermo Scientific range of ICP-OES and ICP-MS instrumentation enables users to comply with the regulatory additions while delivering accurate and repeatable results.”

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

About Thermo Fisher Scientific
Thermo Fisher Scientific, Inc. (thermoscientific.com) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

For further press information please contact: Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom T: + 44 1477 539 539, F: +44 1477 539 540, E: thermo[.]scottpr.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Celine Callender - Scottpr.com 
+1 800-532-4752 analyze[.]thermofisher.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)